Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
72
RIGL Quote, Financials, Valuation and Earnings
Last price:
$41.63
Seasonality move
:
-1.35%
Day range:
$41.58 - $43.56
52-week range:
$14.63 - $52.24
Dividend yield:
0%
P/E ratio:
6.74x
P/S ratio:
2.71x
P/B ratio:
6.42x
Volume:
1.4M
Avg. volume:
632K
1-year change:
141.66%
Market cap:
$754.9M
Revenue:
$179.3M
EPS (TTM):
$6.17
Analysts' Opinion
-
Consensus RatingRigel Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $49.60, Rigel Pharmaceuticals, Inc. has an estimated upside of 19.26% from its current price of $41.59.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $38.00 representing 100% downside risk from its current price of $41.59.
Fair Value
-
According to the consensus of 5 analysts, Rigel Pharmaceuticals, Inc. has 19.26% upside to fair value with a price target of $49.60 per share.
RIGL vs. S&P 500
-
Over the past 5 trading days, Rigel Pharmaceuticals, Inc. has overperformed the S&P 500 by 1.88% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Rigel Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Rigel Pharmaceuticals, Inc. has grown year-over-year revenues for 7 quarters straight. In the most recent quarter Rigel Pharmaceuticals, Inc. reported revenues of $69.5M.
Earnings Growth
-
Rigel Pharmaceuticals, Inc. has grown year-over-year earnings for 7 quarters straight. In the most recent quarter Rigel Pharmaceuticals, Inc. reported earnings per share of $1.46.
Enterprise value:
678.6M
EV / Invested capital:
--
Price / LTM sales:
2.71x
EV / EBIT:
5.71x
EV / Revenue:
2.41x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
9.96x
Price / Operating cash flow:
11.21x
Enterprise value / EBITDA:
5.59x
Gross Profit (TTM):
$262.6M
Return On Assets:
45.04%
Net Income Margin (TTM):
40.17%
Return On Equity:
273.99%
Return On Invested Capital:
111.09%
Operating Margin:
40.92%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $132.4M | $157.5M | $282.1M | $55.3M | $69.5M | |
| Gross Profit | $128.7M | $140.8M | $262.6M | $47.3M | $64.7M | |
| Operating Income | -$19.1M | $9.5M | $119M | $14.1M | $28.4M | |
| EBITDA | -$17.8M | $11.4M | $121.4M | $14.7M | $29M | |
| Diluted EPS | -$1.41 | $0.22 | $6.17 | $0.70 | $1.46 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $171.1M | $110.4M | $95M | $106.5M | $214.9M | |
| Total Assets | $186.5M | $115.6M | $115.3M | $139.4M | $242.5M | |
| Current Liabilities | $59.3M | $47.3M | $48.3M | $54.3M | $94.4M | |
| Total Liabilities | $136.8M | $135.4M | $147.2M | $154.1M | $124.9M | |
| Total Equity | $49.7M | -$19.8M | -$31.8M | -$14.6M | $117.6M | |
| Total Debt | $28.7M | $45.2M | $60.1M | $59.8M | $60.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$21.4M | $10.7M | $68.2M | $21.7M | $24M | |
| Cash From Investing | $21.2M | $8.2M | -$77.9M | $3.8M | -$33.2M | |
| Cash From Financing | $15.8M | -$12.6M | $6.6M | -$9.8M | $4.3M | |
| Free Cash Flow | -$36.5M | $10.4M | $68.1M | $21.7M | $24M | |
RIGL
Sector
Market Cap
$754.9M
$27.9M
Price % of 52-Week High
79.61%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-1.31%
-1.49%
1-Year Price Total Return
141.66%
-16.66%
Beta (5-Year)
1.110
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$41.73
200-day SMA
Buy
Level
$27.66
Bollinger Bands (100)
Buy
Level
29.17 - 43.09
Chaikin Money Flow
Sell
Level
-15M
20-day SMA
Sell
Level
$45.09
Relative Strength Index (RSI14)
Sell
Level
48.40
ADX Line
Sell
Level
22.18
Williams %R
Buy
Level
-80.7915
50-day SMA
Buy
Level
$38.13
MACD (12, 26)
Buy
Level
0.45
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
38.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.8809)
Sell
CA Score
(Annual)
Level (-2.3638)
Sell
Beneish M-Score
(Annual)
Level (-0.3376)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (2.2711)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, RIGL has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The RIGL average analyst price target in the past 3 months is $49.60.
-
Where Will Rigel Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Rigel Pharmaceuticals, Inc. share price will rise to $49.60 per share over the next 12 months.
-
What Do Analysts Say About Rigel Pharmaceuticals, Inc.?
Analysts are divided on their view about Rigel Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rigel Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $38.00.
-
What Is Rigel Pharmaceuticals, Inc.'s Price Target?
The price target for Rigel Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $49.60 according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is RIGL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Rigel Pharmaceuticals, Inc. is a Buy. 3 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RIGL?
You can purchase shares of Rigel Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rigel Pharmaceuticals, Inc. shares.
-
What Is The Rigel Pharmaceuticals, Inc. Share Price Today?
Rigel Pharmaceuticals, Inc. was last trading at $41.63 per share. This represents the most recent stock quote for Rigel Pharmaceuticals, Inc.. Yesterday, Rigel Pharmaceuticals, Inc. closed at $41.59 per share.
-
How To Buy Rigel Pharmaceuticals, Inc. Stock Online?
In order to purchase Rigel Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RIGL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RIGL
Sector
P/E ratio
6.74x
23.85x
PEG ratio
0.00x
-0.01x
P/B ratio
6.42x
1.81x
Price / LTM sales
2.71x
1.58x
Growth Metrics
RIGL
Sector
Revenue growth
25.59%
4.62%
Earnings growth
106.95%
10.5%
Revenue (5-year growth)
24.77%
6.5%
Earnings forecast
$0.80
-$0.21
Profitability
RIGL
Sector
Profitability FY 2024
$160.6M
$3.6M
Return on invested capital
111.09%
-31.87%
Return on assets
45.04%
-28.18%
Return on equity
273.99%
-37.63%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Mar
3
Estimated Next Earnings Date
Feb
3
Balance Sheet
RIGL
Sector
Total cash
$137.1M
$26.4M
Short term investments
$20.6M
$25.7M
Total assets
$493.2M
$76.9M
Long term debt
$60.3M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
